

4 November 2024

Physiomics plc
("Physiomics" or the "Company")

Senior Management Announcement

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Mark Davies, as Head of Quantitative Pharmacology and Data Science.

Dr Mark Davies brings over 20 years' experience in drug development, both from the perspective of working within major pharmaceutical companies (such as AstraZeneca) as well as from within service businesses supporting biopharma companies worldwide. During this time, his roles have spanned a variety of different disease areas and phases of drug discovery and development. His main areas of experience are within computational biology and data informatics bringing a collaborative approach to improve how companies work with and analyse datasets from different sources. He has numerous peer-reviewed publications and broad experience in experimental techniques, informatics and their applications to modelling, helping to answer critical questions in drug discovery. More recently, he has worked in business development roles for state-funded (Medicines Discovery Catapult) and multiple Contract Research Organisations (service providers) across Europe, bringing a consultative approach to the utility of informatics-based approaches to questions in the healthtech and pharmaceutical industry. Mark has a PhD in Biological Sciences, from the University of Warwick, UK, and B.Sc in Biochemistry from University of Bath, UK.

This new senior role will be responsible for the Company's Modelling, Simulation and Data Science service line and will work closely with the CEO and Board on setting its overall strategic direction. Dr Davies' focus will be to drive growth and operational excellence in this service area. He will work closely with the Head of Business Development to expand our services and market reach, helping to accelerate conversion of new opportunities into contracts. From an operational standpoint, the role will provide operational governance and line-management of the technical team, ensuring efficient delivery of high-quality consultancy projects.

Dr Peter Sargent, CEO, commented: *"We are delighted to welcome Mark to our team. We feel that his unique mix of technical and commercial experience spanning across modelling & simulation, data science and drug development, he will be a great addition to the Company".*

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Limited (NOMAD)
James Dance & James Bellman

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFIFVALVLLIIS